MDWD vs MDXG
MDWD: MediWound is a biopharmaceutical developer specializing in enzymatic debridement technology for burn wound and tissue repair. MDXG: MiMedx is a regenerative medicine company specializing in placental tissue-based therapies for advanced wound care and surgical applications.
Side-by-side fundamentals
| Metric | MDWD | MDXG | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $12.42 | $4.62 | |
| Market cap | $174M | $673M | |
| P/E as of 2026-10-08 | n/a | 116.96 | |
| Net margin FY2025, SEC XBRL | -140.8% | +11.6% | MDXG higher |
| Gross margin FY2025, SEC XBRL | +19.2% | +82.6% | MDXG higher |
| Operating margin FY2025, SEC XBRL | -149.0% | +15.3% | MDXG higher |
| ROE FY2025, SEC XBRL | -54.7% | +18.9% | MDXG higher |
| ROA FY2025, SEC XBRL | -27.7% | +14.2% | MDXG higher |
| Debt / equity as of 2026-09-03 | 0.20 | 0.08 | MDXG lower |
| Revenue growth (YoY) as of 2026-09-03 | -24.6% | -2.4% | MDXG higher |
| Revenue CAGR (3y) SEC XBRL | -13.8% | +16.1% | MDXG higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.71 | 0.64 | |
| 1-year return as of 2026-10-08 close | -29.5% | -34.9% | MDWD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.